Cell and Gene Therapy Supply Chain/Logistics Market Report 2026

The cell and gene therapy supply chain/logistics market size has grown rapidly in recent years. It will grow from $1.58 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing complexity of cell and gene therapy logistics, early adoption of cryogenic shipping solutions, expansion of centralized manufacturing models, growing regulatory focus on traceability, rising use of specialized logistics providers.

The cell and gene therapy supply chain/logistics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing commercialization of personalized therapies, rising demand for end-to-end supply chain visibility, expansion of global therapy distribution networks, growing adoption of cloud-based logistics platforms, increasing investments in smart cold chain infrastructure. Major trends in the forecast period include expansion of integrated cold chain management platforms, growing adoption of real-time tracking and traceability systems, rising use of cryogenic logistics solutions, increasing integration of patient-centric supply chain models, enhanced focus on chain of custody compliance.

The growing demand for cell and gene therapies is driving the cell and gene therapy supply chain and logistics market. Cell and gene therapies are advanced medical treatments that alter cells or genes to treat diseases, providing potential solutions for previously untreatable conditions. These therapies require precise temperature and storage conditions, which can be maintained through supply chain and logistics services that manage everything from sourcing to distribution and storage of these treatments. For example, in 2023, the American Society of Gene & Cell Therapy, a U.S.-based non-profit medical and scientific organization, reported that the number of gene therapies in Phase III clinical trials increased by 10% in Q3 2023, marking the first quarterly growth since Q3 2022. Consequently, the rising demand for cell and gene therapies is propelling the cell and gene therapy supply chain and logistics market forward.

Modern technology platforms are emerging as a key trend in the cell and gene therapy supply chain and logistics markets. Leading companies in the market are developing advanced technology platforms for cell and gene therapies to maintain their competitive position. For example, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company specializing in cell and gene therapy supply chain logistics, launched the Cell and Gene Therapy (CGT) Integration Hub. This Hub is powered by AmerisourceBergen’s innovative customer relationship management (CRM) system and can be integrated into the biopharma platform to enable improved monitoring of the development and delivery of cell and gene therapies.

In October 2025, Peli BioThermal, a US-based provider of temperature-controlled packaging solutions, acquired EVO for an undisclosed amount. Through this acquisition, Peli BioThermal aims to expand its cold chain capabilities, enhance service offerings for temperature-sensitive shipments, strengthen its global logistics network, and support growth in life sciences and healthcare markets. EVO is a US-based cold chain company that provides supply chain and logistics solutions for cell and gene therapies.

Major companies operating in the cell and gene therapy supply chain/logistics market are AmerisourceBergen Corporation, United Parcel Service, Thermo Fisher Scientific Inc., Avantor Sciences, Lonza Group AG, Arvato Group, Catalent Inc., Charles River Laboratories International, Parexel International Corporation, Cytiva, Almac Group, World Courier, Sharp Packaging Services, PCI Pharma Services, Cryoport Inc., Brooks Life Sciences, BioLife Solutions Inc., Biocair Inc., QuickSTAT, Clarkston Consulting Inc., Central Pharma, TrakCel limited, MAK-SYSTEM International Group, Hypertrust Patient Data Care GmbH, Atelerix Ltd., Polar Express Transportation, Be The Match BioTherapies Inc., Yourway Biopharma Services Company, Azenta Life Sciences Inc., Biostor Ltd.

North America was the largest region in the cell and gene therapy supply chain/logistics market in 2025. The regions covered in the cell and gene therapy supply chain/logistics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy supply chain/logistics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell and gene therapy supply chain and logistics market by increasing costs of imported cryogenic shippers, ultra-low freezers, tracking sensors, and cold-chain software systems. Logistics providers in North America and Europe are most affected due to dependence on specialized imported equipment, while Asia-Pacific faces cost pressure on cross-border shipment operations. These tariffs are increasing logistics costs and operational complexity. However, they are also encouraging domestic manufacturing of cold-chain components, regional logistics hubs, and greater resilience across advanced therapy supply chains.

The cell and gene therapy supply chain/logistics market research report is one of a series of new reports that provides cell and gene therapy supply chain/logistics market statistics, including cell and gene therapy supply chain/logistics industry global market size, regional shares, competitors with a cell and gene therapy supply chain/logistics market share, detailed cell and gene therapy supply chain/logistics market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy supply chain/logistics industry. This cell and gene therapy supply chain/logistics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell and gene therapy supply chains and logistics encompass the processes and activities involved in efficiently and effectively managing the flow of materials, information, and resources required to develop, manufacture, and deliver cell and gene therapies from initial production to final administration to patients. These services ensure the provision of advanced treatments to patients while upholding the highest standards of safety and efficacy throughout the supply chain.

The primary types of software solutions include cell orchestration platforms, enterprise manufacturing systems, inventory management systems, laboratory information management systems, logistics management systems, patient management systems, quality management systems, and tracking and tracing systems. A cell orchestration platform is a software or technological solution that enables the coordination, management, and integration of various processes involved in cell therapy development, manufacturing, and delivery. It helps streamline and automate tasks related to cell sourcing, manufacturing, quality control, logistics, patient tracking, and data management. These platforms can be deployed as cloud-based solutions, on-premises solutions in cryogenic shippers, cryogenic storage freezers, ultra-low freezers, cold chain management systems, shipment and storage media, cryogenic packout kits, and other components. They are used in applications such as donor eligibility assessment, sample collection, manufacturing, logistics, patient verification, and treatment follow-up by end users including biobanks, cell therapy laboratories, hospitals, research institutes, and commercial organizations.

The cell and gene therapy supply chain and logistics market includes revenues earned by entities by providing sourcing and collection, quality testing, distribution, and transportation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.